Kite Pharma join forces with Leukemia & Lymphoma Society
KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
Rociletinib is the Company’s novel, oral targeted covalent (irreversible) mutant-selective inhibitor of EGFR in development for the treatment of NSCLC in patients with initial activating EGFR mutations, as
RHB-104 is an antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. Currently, RHB-104 is undergoing a first Phase III study for Crohn’s